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Summary
The genetic mechanisms responsible for increased incidence of lymphoma in immunocompromised individuals have not
been fully elucidated. We show that, in a line of TCR transgenic TG-B mice, an insertional mutation in one allele of the
Epm2a locus and epigenetic silencing of another led to a high rate of lymphoma with early onset. Overexpressing Epm2a
suppressed the growth of established tumor cells and the development of lymphoma in the TG-Bmice, while specific silenc-
ing of the locus increased tumorigenesis in the immune-deficient host. Downregulation of Epm2a expression is widespread
among mouse and human lymphoma cell lines. Epm2a-encoded laforin is a phosphatase for GSK-3b and an important
repressor in the Wnt signaling pathway. Inactivation of Epm2a resulted in increased Wnt signaling and tumorigenesis.Introduction
Significant increases in cancer rate have been reported in im-
mune-deficient individuals, including those infected with the hu-
man immune-deficient virus (HIV) (Boshoff andWeiss, 2002) and
transplantation patients under constant immune suppression
(Penn, 1995, 1996). These observations support the notion
that T cell-mediated immunity serves as a major barrier for the
development of cancer (Dunn et al., 2002). On the other hand,
mice with defective T cell immunity, such as nudemice (Rygaard
and Povlsen, 1974), do not appear to have a major increase in
the rate of spontaneous cancer. An intriguing possibility is that
other genetic defects may act in concert with immunodeficiency
to cause cancer. While defects in bona fide cancer suppressor
genes have been shown to synergize with immune deficiency
in the development of spontaneous cancer (Liao and Van
Dyke, 1999; Liao et al., 1998), it is unknown whether a different
class of cancer suppressor genes exists that can cause cancer
primarily in an immune-deficient host.
The T cell receptor (TCR) transgenic mice have random coin-
tegration of the genes encoding for the a and b chains of the TCR
into the genome. Because of the allelic exclusion, expression of
the transgenic TCR represses the endogenous TCR. As a result,CANCER CELL 10, 179–190, SEPTEMBER 2006 ª2006 ELSEVIER INC. Dthe host is substantially devoid of T cells with the capacity to
combat cancer cells. Nevertheless, the development of cancer
in TCR transgenic mice has rarely been observed. Occasionally,
thymoma was reported in TCR transgenic mice late in life
(around 2 years of age) (Reimann et al., 1994). This general ex-
perience is consistent with the notion that limiting TCR reper-
toire is insufficient to cause cancer development. We made
a serendipitous observation that one line of TCR transgenic
mice, called TG-B mice (Geiger et al., 1992), developed T cell
lymphoma with almost 100% penetrance and a median survival
of 6 months. Since lymphoma of such severity is unprecedented
in TCR transgenic mice, we carried out position cloning in order
to identify the genetic basis for the malignancy. We found that
the transgenes were inserted in intron 1 of Epm2a, which was
initially identified as one of the causative genes for progressive
myoclonus epilepsy (Ganesh et al., 1999, 2000; Minassian
et al., 1998). The function of Epm2a as a tumor suppressor is fur-
ther confirmed by specific silencing and by transfection studies.
Moreover, we have found that laforin is a phosphatase for GSK-
3b and Epm2a inactivation is associatedwith enhancedWnt sig-
naling. The activated Wnt signaling pathway is essential for the
development of cancer in an immunodeficient host. Our results
demonstrate that Epm2a is a tumor suppressor gene in anS I G N I F I C A N C E
Immune surveillance is an important concept in cancer biology and immunology. An important issue is whether specific genetic al-
teration may be associated with cancer development in an immunocompromised host. Our data showed that Epm2a alteration
may be such a genetic factor and thus provide strong support for the concept of immune surveillance. Moreover, identification of la-
forin as a regulator for Wnt signaling and GSK-3b phosphorylation may suggest a broad function of laforin in cellular physiology.OI 10.1016/j.ccr.2006.08.008 179
A R T I C L EFigure 1. A transgenic mouse line developed
lymphoma with high penetrance and early le-
thality
A: The survival distribution function among
B10.BR and TG-B male and female mice. The inci-
dence of lymphoma is significantly higher
among TG-B in comparison to wild-type (p <
0.0001) mice.
B: Enlargement of spleen, thymus, and mesen-
teric lymph node (MLN) in a TG-B mouse with tu-
mor (left panels). Organs from a TG-B mouse that
have not developed tumor are shown as con-
trols.
C: Immunohistochemical staining of anti-Thy1 in
non-Tg spleen showing normal T cell distribution
(Ca) and in spleen from TG-B mouse with lym-
phoma showing that the entire spleen was infil-
trated by large lymphoblastic T cells (Cb). H&E
sections of liver (Cc) and kidney (Cd) of the tu-
mor-bearing TG-B mice show the infiltration of
lymphoma cells in organs.
D: Immunophenotypes of the lymphomas by
flow cytometry. Normal thymic cells or lympho-
matous thymic cells were stained with anti-
bodies against CD4, CD8, and Vb8. Da: Normal
thymic cells showed the TCR transgenic pheno-
type with skewed CD8+ single-positive cells and
predominantly Vb8+ transgenic cells (Geiger
et al., 1992); Db: a thymoma with predominantly
high Vb8+ mature single CD8+ cells; Dc: a thy-
moma with immature CD4+CD8+ cells and lower
levels of Vb8; Dd: a lymphoma with immature sin-
gle positive (ISP) CD8+ (a T cell development
stage between double-negative and double-
positive) without any Vb8 expression.immunocompromised host and an important modulator of Wnt
signaling.
Results
Transgene insertion to and hypermethylation of the
Epm2a gene induces spontaneous lymphoma
in TG-B transgenic mice
The TG-B transgenic mice used in this study have rearranged T
cell receptor a and b chain genes isolated from a clonal CD8+ cy-
totoxic T cell line. The TCR transgenes were integrated into the
genome of the B10.BR (H-2k) mice (Geiger et al., 1992). Surpris-
ingly, the heterozygous TG-B mice had a high incidence of lym-
phoma regardless of sex. The maximal survival time for TG-B
mice was 9 months, with a median survival time of 6 months
(Figure 1A). The lymphomawas first seen in lymphoid organs, in-
cluding the thymus, spleen, and lymph nodes (Figure 1B). As the
cancer progressed, the tumor cells infiltrated other organs, such
as the liver, kidney (Figure 1C), lung, pancreas, intestines, and
salivary glands (data not shown). The immunophenotype of
the T cell lymphoma varied between animals, suggesting that180transformation occurred at various stages in T cell development
(Figure 1D).
We determined the integration site of the transgene by
fluorescence in situ hybridization (FISH) using a biotin-labeled
DNA fragment probe from the TCRa chain constant region
(Heng et al., 1992). A strong signal was identified on one copy
of chromosome 10 (Figure 2A). The strong signal was localized
to region 10A2 based on the summary of ten images (data not
shown). Two weaker FISH signals were detected, one on each
copy of chromosome 14, which was consistent with the location
of the endogenous TCRa genes. Fine mapping of integration
sites was performed by the TOPO Walker method (Shuman,
1994). PCR products using the TOPO Linker primers and the
gene-specific sequence primers from both the 30 and 50 termini
of the TCRa and TCRb transgenes were cloned and sequenced.
Three independent experiments revealed that the TCRa trans-
gene was inserted into the intron 1 of Epm2a, which encodes la-
forin, a dual specificity protein phosphatase (Figure 2B) (Minas-
sian et al., 1998; Serratosa et al., 1999). Further PCR analysis
using primers corresponding to the 30 terminus of the TCRa
transgene and the 50 terminus of the TCRb transgene confirmed
that these genes were cointegrated into chromosome 10 inCANCER CELL SEPTEMBER 2006
A R T I C L EFigure 2. Identification of the integration site of the TCR transgene
A:Cytogenetic analysis of TCR gene localization by FISH. The probe used was the constant region of the TCRachain. The location of the transgene is indicated
by an arrow in the FISH image (left panel), and the positions of chromosomes 10 and 14 are marked in the DAPI staining (right panel). The signals in chromo-
some 14 reflect the location of the endogenous TCRa loci. The signal in chromosome 10 is the transgene insertion locus.
B: Fine mapping of the TCR integration site. A representative chromatogram depicting the junction region sequence is shown at the top, and the alignments
of this sequence to those of mouse chromosomes 10 and 14 are shown in the middle. The bottom panel shows a portion of mouse chromosome 10A2 surround-
ing the integrating site as annotated in the Celera database; note that the integrating site is in intron 1 of Epm2a.
C: Chromatogram depicting the junctional sequence of TCRa and b constructs.
D: Confirmation of the integration site by Southern blot. The restriction enzyme map of endogenous and Tg alleles and a Southern blot autograph are shown.TG-Bmice (Figure 2C). The integration was confirmed by South-
ern blot using the sequence adjacent to the integration site as
probe (Figure 2D). Additional chromosomal walking with the
b chain probe failed to identify other integration sites for the
TCRb construct (data not shown).
We examined the expression of the Epm2a gene in the thymi
of nontransgenic mice (NTg), transgenic littermates with no
tumor (Tg), and transgenic mice that developed lymphoma
(Tg-Tu). Based on RT-PCR amplification of full-length transcript,
Epm2awas expressed at significant levels in nontransgenic and
transgenic littermates. However, its expression in Tg-Tu lym-
phoma cells was greatly reduced (Figure 3A). RNase protection
assay using an Epm2a probe spanning exons 3 and 4 did not
find any Epm2a transcript containing either one of the two exons
in Tg-Tu lymphoma (Figure 3B). Using a polyclonal antibody
against laforin, we showed that laforin was expressed in Tg
mice with approximately half of the amount in NTg mice but
was absent in the transgenic mice that developed lymphoma
(Tg-Tu) (Figure 3C). Moreover, we observed downregulation of
laforin in the majority of the murine T and B cell lymphoma cell
lines that we tested (Figure 3D). Thus, tumorigenesis was con-
sistently associated with altered laforin gene expression. Inter-
estingly, the high tumor incidence and lack of laforin that areCANCER CELL SEPTEMBER 2006documented in Figure 1A were observed in heterozygous
mice. To determine whether loss of heterozygocity is responsi-
ble for tumor development, we genotyped tumor cells for the
presence of wild-type and disrupted Epm2a alleles. As shown
in Figure 3E, all tumor cells had both wild-type and disrupted
alleles (Figure 3E).
The Epm2a gene contains a 1.2 kb 50-CpG island that spans
the promoter region, exon 1, and part of intron 1 (Figure 4A).
To determine if DNA hypermethylation was an epigenetic mech-
anism for laforin gene downregulation in TG-B lymphoma, we
treated the genomic DNA with bisulfite and sequenced four
PCR products covering 102 CpG dinucleotides within the 50-
CpG island. Based on methylation-mediated protection of C>T
conversion by the sodium bisulfite, we identified the methylated
CpG dinucleotides. As illustrated in Figure 4B, extensive hyper-
methylation was found in the Epm2a gene of all six lymphoma
samples. In contrast, none of the normal thymi had methylation
in this region.
Our survey of multiple lymphoma cell lines revealed that
downregulation of Epm2a gene expression was widespread
among murine lymphomas (Figures 3E and 4C). We compared
three nonlymphoid tumor cell lines with three T lymphoma cell
lines for 5-aza-20-deoxycytidine (5-Aza-dC)-induced Epm2a181
A R T I C L EFigure 3. Reduced expression of laforin in lym-
phoma
A: Defective expression of Epm2a mRNA in trans-
genic mice with lymphoma (Tg-Tu), but not in the
nontransgenic littermates (NTg), or in young
transgenic mice that have not yet developed
lymphoma (Tg).
B: RNase protection assay showing no truncated
Epm2a transcript in Tg-Tu. The probe used
spanned exons 3 and 4.
C: Absence of laforin protein expression in Tg-Tu
lymphoma cells and reduction of laforin expres-
sion in thymi from young transgenic (Tg) mouse
by Western blot.
D: Downregulation of laforin protein in multiple
murine malignancies of T and B cell lineages.
The thymocytes from a nontransgenic littermate
(Ntg) and two transgenic mice with lymphoma
(Tg-Tu) were examined as control. The malignant
cell lines used were EL4, YAC-1, BW5147, RMA-S
(T cell lymphoma), A20, RAW8.1, CH27 (B cell
lymphoma), and S194 (myeloma). Data shown
are representative of three independent experi-
ments.
E: Thymoma in TG-B mice retained both wild-type
and disrupted Epm2a alleles. Genomic DNA was
isolated from NTg, Tg, and Tg-Tu thymi. PCR reac-
tions were performed using a forward primer in
chromosome 10, paired with a reverse primer
from chromosome 10 or a reverse primer from
TCRa chain constant region.expression. As shown in Figure 4C, treatment withmethyl-trans-
ferase inhibitor 5-Aza-dC increased Epm2a expression in three
T lymphoma cell lines but had little effect on three nonlymphoid
tumor cell lines that had relatively high levels of Epm2a expres-
sion. To test whether hypermethylation of the Epm2a promoter
was responsible for repression of the Epm2a gene, we deter-
mined the Epm2a promoter hypermethylation by quantitative
real-time PCR based on susceptibility to amethylation-sensitive
restriction enzyme, SacII. Epm2a promoter region DNA from
mouse no. 4012 had been treated with bisulfite and sequenced
to show there was 100% CpG methylation, but promoter region
frommouse no. 11992was notmethylated (Figure 4B). Genomic
DNA from mouse 4012 and mouse 11992 was used as positive
and negative controls in this assay. As shown in Figure 4D, real-
time PCR showed similar amplification between three T cell lym-
phomas and control mouse 4012, indicating that T cell lympho-
mas had similar hypermethylation in the Epm2a promoter region
and their genomic DNA was resistant to SacII digestion. In
contrast, genomic DNA from three nonlymphoid tumor cell lines
was not methylated and was sensitive to SacII digestion; there-
fore, real-time PCR failed to amplify the SacII fragmented
Epm2a promoter region. These data are consistent with the
notion that hypermethylation is responsible for Epm2a downre-
gulation among T lymphomas.
Inactivation of the Epm2a locus is necessary
and sufficient to initiate cancer development
There are two genes within 300 kb of the transgene integration
site. The proximal gene is 56 kb away from the integration site
and encodes a protein that contains an F box domain
(mCG16603), while the other gene is 135 kb from the integration
site (mCG140768) (Figure 5A). We performed RNase protection
assay to determine the mRNA expression of these two genes.
The expression level of the distal gene (mCG140768) was not182affected by the transgene or lymphoma development, while
the expression of the proximal gene (mCG16603) was upregu-
lated by the transgene regardless of lymphoma formation (Fig-
ure 5B). We tested this possibility by producing eight indepen-
dent founders of transgenic mice that expressed mCG16603
under the control of a proximal lck promoter, which resulted in
high levels of expression in the thymus. None of the mice devel-
oped lymphoma in up to 22 months of observation (Figure 5C).
The offspring of one of the founders were observed over a 1 year
period. Although mCG16603 was expressed at much higher
levels than in the TG-B mice (Figure 5D), no lymphoma was ob-
served in the 12 mice observed over a 45–61 week period (Fig-
ure 5C). Thus, lymphoma development in the TG-B mice was
unlikely caused by the abnormal expression of other genes
near the integration site, although the possibility that the overex-
pression of mCG16603 may promote cancer development in
this model cannot be completely ruled out at this stage.
To test whether inactivation of the Epm2a gene is sufficient to
cause abnormal cell growth, we tested the consequences of si-
lencing the Epm2a gene in the bone marrow stem cells in both
methylcellulose assay in vitro and bone marrow reconstitution
in vivo. Unmanipulated murine bone marrow had a finite ability
to self-renew in methylcellulose cultures supplemented with
cytokines (Lavau et al., 1997). We constructed lentiviral vectors
expressing C-terminal siRNA for Epm2a or control sequence. In-
fection with a virus containing C-terminal siRNA for Epm2a re-
sulted in complete silencing of the Epm2a gene in fibroblast
(Figure 6A). Bone marrow cells from B10.BR mice pretreated
with 5-fluorouracil (5-FU) were transduced with the siRNA or
control viruses and selected for blasticidin-resistant transduced
cells in the first plating in methylcellulose. Cells were cultured
in vitro for four serial replatings, and the number of colonies
was counted under a microscope. As shown in Figure 6B, the
number of colonies formed from 104 vector-transduced boneCANCER CELL SEPTEMBER 2006
A R T I C L EFigure 4. Epm2a is hypermethylated in lym-
phoma cells
A: Diagram of the 50-CpG island and the four
PCR fragments amplified using bisulfite-treated
DNA to examine the methylation status of the
Epm2a gene with number of CpG dinucleotides
in each fragment indicated in parentheses.
B: Summary of the results of bisulfite sequencing
of 333bp PCR products that contained 45 CpG
dinucleotides. Fifty-seven clones were obtained
from six lymphoma TG-B mice (Tg-Tu) (the mouse
ID number is shown with clone numbers from
each mouse labeled in parentheses), and 45
clones were obtained from six transgenic litter-
mates without lymphoma (Tg). Each circle repre-
sents the methylation status of a CpG dinucleo-
tide. Methylated and unmethylated alleles are
shown as solid and open circles, respectively.
C: 5-Aza-dC-induced Epm2a expression in lym-
phoma cell lines (EL4, YAC-1, and BW5147), but
not in three nonlymphoid tumor cell lines (colon
cancer MC38, mastocytoma P815, fibrosar-
coma Meth A).
D: Epm2a promoter methylation in lymphoma
cell lines. The y axis is the fraction of the real-
time PCR products from methylation-sensitive
SacII-digested genomic DNA compared with
that from undigested genomic DNA and is plot-
ted in log scale. We used samples with 100%
methylation (mouse 4012) and no methylation
(mouse 11992) as determined in Figure 4B as pos-
itive and negative controls for the assay. The
fraction between SacII post- and predigested
samples with 100% methylation was defined as
1.0. All other samples were normalized accord-
ingly. Data shown are means and SD of triplicate
samples and have been repeated twice.marrow cells was steadily reduced over serial replatings. In
striking contrast, cells transduced with Epm2a siRNA had a
drastic increase in the number of colonies in the third and fourth
rounds, most of them tightly packed. These results demonstrate
that silencing Epm2a drastically increases the self-renewal
ability of the bone marrow stem cells.
To test whether silencing Epm2a in the bonemarrow cells can
cause hematological abnormality in vivo, we injected the siRNA-
transduced or control vector-transduced BALB/c P1CTL TCR
transgenic mouse (Sarma et al., 1999) bone marrow cells into ir-
radiated syngeneic RAG-22/2 mice. The mice were examined
4 months after bone marrow reconstitution, as the mice in the
siRNA group started to lose weight and had difficulty in breath-
ing. The random integration of the viral constructs in the bone
marrow cells was confirmed by Southern blot (Figure 6C). Exam-
ination of the bone marrow showed that in the chimera mice
reconstituted with control vector-transduced bone marrow the
myeloid over erythroid ratio was normal at 2. This ratio was dras-
tically increased to 5.3 in four out of five recipients of siRNA-
transduced bone marrow cells (p = 0.004) (Figure 6D). TheCANCER CELL SEPTEMBER 2006increased M/E ratio was due to the increase in segmental and
band neutrophils and decreased erythroid cells in the bonemar-
row. In addition, we observed an increased cellularity of the
bone marrow in the siRNA-transduced group (Figures 6Ea and
Eb). The fifth recipient of siRNA-transduced bone marrow had
about 48% of monocytes and monoblasts in the bone marrow
(Figure 6Ec) compared to less than 2% in the control group
(Figure 6Ea), which is consistent with the diagnosis of chronic
myelomonocytic leukemia. The cause of respiratory distress in
the recipient mice that received siRNA-transduced bone
marrow was due to a heavy infiltration of monocytic cells and
fibroblastic proliferation in the lung tissue (Figure 6Ed). The
homogenous infiltrating cells had abundant cytoplasm, large
indented and lobulated nuclei that had one to three conspicuous
nucleoli per nucleus, and active mitotic figures (Figure 6Ee). In
order to confirm that the malignant infiltrating cells had integra-
tion of the lentiviral construct, we carried out a PCR in situ hy-
bridization assay using the blasticidin resistance gene as probe.
The results showed that the large cluster of infiltrating cancer
cells contained the silencing vector (Figure 6Ef). These results,183
A R T I C L EFigure 5. Overexpression of genes adjacent to
the TCR transgene integration site does not
lead to tumorigenesis
A: Genomic organization of Epm2a and the only
two other genes within 300 kb of the integration
site on chromosome 10. The cDNA designations
are based on Celera database.
B: Expression of the two adjacent genes in non-
transgenic littermates (Ntg), transgenic mice
without tumor (Tg), and transgenic mice that de-
veloped tumor (Tg-Tu), as determined by RNase
protection assay.
C: Summary of observation period of eight trans-
genic founder mice and 12 offspring of the
founder 6 all express mCG16603 under the con-
trol of the proximal lck promoter.
D: The offspring of founder 6 (mouse F392) over-
express the mCG16603 gene, as determined by
real-time PCR. Data shown are means and SD
of triplicate samples and have been repeated
twice.taken together, demonstrate that silencing Epm2a resulted in
myelodysplastic syndrome.
Since the above experiments involved mice or bone marrow
that would produce only limited TCR repertoire, we have ex-
tended this analysis to determine whether immune deficiency
is a precondition associated with cancer development. We first
tested whether silencing Epm2a in the nontransgenic BALB/c
bone marrow resulted in hematological abnormalities after the
cells were used to reconstitute the RAG-2-deficient host. The
BALB/c bone marrow successfully reconstituted the RAG-2-
deficient mice, as demonstrated by the emergence of T cells,
which could only be produced from donor cells. Pathological
evaluation of the five recipients of Epm2a-silenced bonemarrow
at 4.5 months after transplantation revealed none of the abnor-
malities observed with the transgenic bone marrow. Thus, inac-
tivation of Epm2a in bone marrow stem cells capable of yielding
a full repertoire of T cells was insufficient to cause hematological
abnormalities.
We also used vector control-treated or Epm2a-silenced
B10.BR bone marrow to reconstitute the irradiated syngeneic
B10.BR hosts in order to determine whether silencing Epm2a
was sufficient to cause hematological malignancy. The
B10.BR background was chosen, as it is the same as the TG-
Bmice except for the lack of the TCR transgene. In experiments
involving a total of ten recipients in each group, we observed no
hematological abnormalities over a 2.5–3.5 month period. Thus,
even in the B10.BR background, silencing Epm2a was insuffi-
cient to cause hematological abnormalities unless the T cell rep-
ertoire was limited by the TCR transgene. Taken together, our
results demonstrate that limited TCR repertoire rather than
B10.BR background was required for tumor development asso-
ciated with defects in Epm2a, although mice with pure B10.BR
background were more susceptible.
To test whether the hematological malignancy in the TG-B
mice could be complemented by Epm2a, we generated
Epm2a transgenic mice (FVB background) under the control of184the lck promoter. Although the FVB background was less sus-
ceptible to lymphoma than the B10.BR background, about
40% of the nontransgenic FVBxTG-B mice succumbed to lym-
phoma in 1 year. Complementation with the Epm2a transgene
drastically decreased the incidence and delayed the onset of
lymphoma (Figure 6F). Thus, Epm2a inactivation is both neces-
sary and sufficient to initiate cancer development in vivo.
To test whether laforin can suppress the growth of other tumor
cells, we transduced T lymphoma cell line BW5147 with either
vector alone or Epm2a-containing lentiviral vectors. After
a short-term drug selection, we compared vector and Epm2a-
transfected tumor cells for their growth in vivo. As shown in
Figure 6G, the overexpression of laforin in Epm2a transfectants
had substantially reduced tumor growth in vivo. The tumor sup-
pression depended on laforin’s phosphatase activity, as inacti-
vating mutation of the phosphatase (C265S) (Wang et al.,
2002) abolished the tumor suppression. We also transfected
the Epm2a cDNA into B104-1-1, a fibroblast cell line trans-
formed by the P185neu oncogene (Schechter et al., 1984). We
inoculated the Epm2a or vector transfected B104-1-1 cell lines
into RAG-22/2 mice that lacked T and B lymphocytes. Based
on the kinetics of tumor growth, it was clear that overexpression
of Epm2a had a significant suppressive effect on B104-1-1 tu-
mor growth (Figure 6H).
Laforin is the phosphatase for GSK-3b
Because laforin suppressed the growth of Her-2/Neu-trans-
formed tumor cells, we explored the possibility that laforin
may be involved in the PI-3K/Akt signaling pathway. We trans-
fected Epm2a cDNA into NIH3T3 cells and evaluated the effect
of laforin on platelet-derived growth factor (PDGF) receptor sig-
naling. We first examined phosphorylation of Akt at Thr473 by
30-phosphoinositide-dependent protein kinase (PDK) (Alessi
et al., 1997). Activation and phosphorylation of PDKwas not sig-
nificantly affected by PDGF in theNIH3T3 cells, regardless of the
expression of laforin. As a result of PDK recruitment, significantCANCER CELL SEPTEMBER 2006
A R T I C L EFigure 6. In vitro and in vivo transformation of
bone marrow stem cells by silencing Epm2a
A: Epm2a-siRNA repressed Epm2a expression in
NIH3T3 cells.
B: Silencing Epm2a in B10.BR bone marrow cells
greatly increased self-renewal of bone marrow
hematopoietic stem cells. The transduced
bone marrow cells (104/well) were serially re-
plated four rounds in methylcellulose, and blasti-
cidin was added in first round. Data shown are
means and SD of colony numbers in triplicate
plates and are representative of three indepen-
dent experiments.
C–E: Hematological disorders associated with si-
lencing Epm2a. The irradiated RAG-2-deficient
recipients of lentivirus-transduced bone marrow
cells were sacrificed at 4 months after reconstitu-
tion. C: Southern blot using the blasticidin-resis-
tant gene as probe showing random integration
of the lentiviral vector in the Epm2a-silenced
bone marrow. Note the distinct pattern in indi-
vidual mice. D: Bone marrow cell counting show-
ing different myeloid/erythroid (M/E) ratio in the
recipients of the vector-transduced (n = 6) or
siRNA-transduced (n = 4) bone marrow cells.
The fifth case with a different presentation was
not included. Data shown are means and SD.
Ea: Representative histology of six vector-trans-
duced bone marrow with clustered normoblasts
(marked inside the circle). Eb: Representative his-
tology of 4/5 of siRNA-transduced bone marrow
with dispersed normoblasts (marked in arrows),
increased cellularity with selective increase in
band, and segmental neutrophils (M/E ratio is
5.8). Ec: The histology of the fifth recipient of
siRNA-transduced bone marrow showing greatly
increased (46% versus 2% in control bone mar-
row) and clustered monocytes and monoblasts
(yellow arrows). Ed: Massive pulmonary infiltra-
tion and consolidation in lung tissues that com-
pletely obliterated the pulmonary parenchyma
from recipients of siRNA-transduced bone mar-
row. Ee: High-power view of lung section show-
ing heavy infiltration of malignant monocytic
cells. A mitotic figure is present. Ef: PCR in situ
hybridization (PCR-ISH) using a DNA probe of
vector origin blasticidin resistance gene showing
intensely positive signals on malignant infiltrating cells. Eg: A consecutive section, which received identical treatments but without PCR primers, was used as
negative control.
F: Epm2a complementation suppresses tumorigenesis associated with the TG-B mice. Epm2a cDNA was inserted into transgenic vector with a proximal lck
promoter. Founder mice with ectopic expression of Epm2a were crossed with the TG-B mice. The survival of the Epm2a+ TG-B (n = 26) and Epm2a2 TG-B
(n = 33) littermates was observed over a 70 week period. The expression of Epm2a in Epm2a+ and Epm2a2 thymocytes as determined by RT-PCR is shown
underneath.
G: Laforin suppresses the growth of murine T cell lymphoma BW5147. BW5147 cells were infected with empty vector only or with lentiviral vector of either wild-
type or C265S mutant Epm2a cDNAs. Polyclonal stable transfectants were injected subcutaneously into the RAG-22/2 BALB/c mice (33 105 cells/mouse). The
growth kinetics is presented. Data shown are means and SD, and represent those from two independent experiments. Expression of the V5-tagged laforin and
the minute amounts of endogenous laforin are shown underneath.
H: Laforin suppresses the growth of the P185neu-transformed NIH3T3 cell line B104-1-1. B104-1-1 cells were transfected with either vector or Epm2a cDNA. Three
stable clones from each group (Vector or Laforin) were injected into the RAG-22/2 BALB/c mice (33 105 cells/mouse). The growth kinetics is presented. Data
shown are means and SD and are representative of two independent experiments. The expression of V5-tagged laforin and the minute amounts of endog-
enous laforin are shown underneath.Akt phosphorylation was observed following PDGF stimulation,
and again, this was only marginally affected by laforin expres-
sion (Figure 7A and Figure S1 in the Supplemental Data available
with this article online). Interestingly, of the three downstream
targets of Akt (Datta et al., 1999) that we examined, namely
FKHR, AFX, and GSK-3b, only GSK-3b phosphorylation on
Ser9 was affected by overexpression of laforin (Figure 7A).
The effect was highly selective, as the phosphorylation of
Tyr216 of GSK-3b and Tyr279 of GSK-3a was not affected byCANCER CELL SEPTEMBER 2006laforin, despite laforin’s intrinsic dual specificity (Figure 7B). To
determine the effect of laforin expression on GSK-3b activity,
we precipitated GSK-3b and performed the in vitro kinase assay
to test its ability to phosphorylate recombinant protein Tau,
a known GSK-3b substrate (Cho and Johnson, 2003). As shown
in Figure 7C, PDGF-induced inhibition of GSK-3b kinase activity
was blocked in laforin-transfected cells. This was consistent
with the effect of laforin on Akt-mediated phosphorylation of
GSK-3b at Ser9.185
A R T I C L EFigure 7. Laforin is a phosphatase of GSK-3b at
Ser9
A: Laforin selectively prevented PDGF-induced
phosphorylation of GSK-3b. Vector- or laforin-
V5-transfected NIH3T3 cells were stimulated
with PDGF for given periods of time. The activa-
tion of PDK (anti-P-Ser241), Akt (anti-P-Ser473),
GSK-3b (anti-P-Ser9), FKHR (anti-P-Ser256), and
AFX(anti-P-Ser193) was analyzed by Western
blot. Total Akt was loading control.
B: Laforin dephosphorylated the P-Ser9 but not
P-Tyr216 of GSK-3b and P-Tyr279 of GSK-3a. Two
stable laforin-transfected clones are presented
(laforin2 and laforin7).
C: Laforin prevented PDGF-induced inactivation
of GSK-3b kinase activity. Vector- or laforin-trans-
fected NIH3T3 cells were stimulated with PDGF
for 30 min. The anti-GSK-3b immunoprecipitates
were used for kinase assay to determine the
GSK-3b kinase activity. Specific phosphorylation
of recombinant Tau was determined by 32P au-
toradiograph. The radioactive intensity in each
lane was normalized based on the amounts of
GSK-3b in each sample as determined by West-
ern blot. The activity of the GSK-3b isolated
from untreated vector transfectants was arbi-
trarily assigned as 1.0. Data shown are means
and SD. Statistical difference was calculated
by Student’s t tests. Two stable laforin-trans-
fected clones are presented (laforin2 and la-
forin12). Data shown are summary of three inde-
pendent experiments.
D: siRNA suppresses endogenous laforin and en-
hances the PDGF-induced phosphorylation of
GSK-3b. The activation of Akt (anti-P-Ser473)
and GSK-3b (anti-P-Ser9) from vector- or siRNA-
transfected NIH3T3 cells was analyzed. b-actin
was the loading control.
E: Physical association between GSK-3b and
laforin. Upper panel shows association of trans-
fected laforin with GSK-3b. Vector- or laforin-
transfected NIH3T3 cells were immunoprecipi-
tated with either control IgG1 or anti-GSK-3b
and blotted with anti-GSK-3b or anti-V5 for V5-
tagged laforin. The lower panel shows associa-
tion between GSK-3b and laforin in untrans-
fected NIH3T3 cells. Laforin was detected by
anti-laforin antibody.
F andG: Laforin dephosphorylates P-Ser9 of GSK-
3b (F) but not P-Ser112 of Bad in vitro (G). P-Ser-9
peptide of GSK-3b was conjugated in bovine se-
rum albumin (BSA), and recombinant soluble Bad protein was phosphorylated by constitutively activated Akt in the presence of ATP. The vector (V)-, Epm2a
(L)-, or Epm2amutant (C265S)-transfected HEK293 cells were lysed and immunoprecipitated with anti-V5 and mixed with substrates. The specific dephosphor-
ylation was detected with anti-p-GSK-3b (Ser9) or anti-p-Bad (Ser112). Protein loading was confirmed by anti-V5 for laforin and anti-Bad. The protein compo-
sition of the precipitates was analyzed by SDS-PAGE and detected by Coomassie blue staining (F, lower panel). Data shown represent three independent
experiments.The selective effect of laforin on phosphorylation of GSK-3b at
Ser9 raised the intriguing possibility that laforin may be the
phosphatase of GSK-3b. We took three approaches to substan-
tiate this hypothesis. First, we eliminated the endogenous laforin
in NIH3T3 cells. Infection with a virus containing C-terminal
siRNA for Epm2a resulted in complete silencing of the Epm2a
gene in NIH3T3 cells (Figure 6A). As shown in Figure 7D, elimina-
tion of laforin expression had no effect on cellular levels of p-Akt,
but as a result of siRNA inhibition of laforin, the p-GSK-3b be-
came detectable even in the absence of PDGF. Furthermore,
upon PDGF stimulation, levels of phospho-GSK-3b in cells
treatedwith siRNAwere higher than those found in vector-trans-
fected control cells. In addition, the specificity of the knockdown186was confirmed, as the biological effect was restored by reintro-
duction of human laforin, which had two base pair mismatches
in the sequence targeted by the siRNA (Figure S2). Thus, laforin
controls GSK-3b phosphorylation at Ser9.
Secondly, we evaluated whether GSK-3b and laforin can
physically associate with each other. We treated the vector
and laforin-transfected NIH3T3 cells with PDGF and immuno-
precipitated GSK-3b protein with either control IgG1 or a mono-
clonal anti-GSK-3b antibody. The precipitates were analyzed by
Western blot with either anti-GSK-3b antibody or the anti-V5
antibodies that detect the V5-tagged laforin protein. As shown
in the upper panel of Figure 7E, anti-GSK-3b, but not control
IgG1, brought down both GSK-3b and V5-tagged laforinCANCER CELL SEPTEMBER 2006
A R T I C L EFigure 8. Laforin modulates the Wnt signaling
pathway
A: Increased GSK-3b phosphorylation and b-cat-
enin nuclear accumulation in the thymocytes
from transgenic mice with lymphoma (Tg-Tu),
but not the normal mice (NTg) and the trans-
genic mice yet to develop lymphoma (Tg).
B: Transfection of laforin suppressed Wnt signal-
ing in NIH3T3 cells. NIH3T3 cells transfected with
either vector or laforin were stimulated with
Wnt-3A and tested for GSK-3b Ser9 phosphoryla-
tion and nuclear accumulation of b-catenin.
C: TCF reporter assay. pTOPFLASH or pFOPFLASH
TCF luciferase reporter vector was cotransfected
with pRL-SV40 Renilla control luciferase reporter
plasmid into Vector (V), laforin, or mutant laforin
(C265S) stably transfected NIH3T3 cells.
D: Laforin expression in tumor cell line B104-1-1
inhibited the GSK-3b Ser9 phosphorylation and
b-catenin nuclear accumulation induced by
recombinant Wnt-3A.
E: Epm2a siRNA increased the GSK-3b Ser9 phos-
phorylation and b-catenin nuclear accumula-
tion induced by recombinant Wnt-3A in NIH3T3
cells.
F: siRNA silencing of laforin expression in the en-
dothelial cell line LExF2-TQ increases its tumorige-
nicity. TQ cells infected with lentiviruses contain-
ing either vector or Epm2a-siRNA were injected
subcutaneously into RAG-22/2 mice (1 3 106/
mouse). The growth kinetics was recorded over
a 2 month period. Data shown represent two in-
dependent experiments with three mice per
group.
G: Increased tumorigenicity of the Epm2a-si-
lenced LExF2-TQ cell line is eliminated by expres-
sion of a dominant-negative TCF-1 mutant
(DTCF-1). As in F, except that the laforin-silenced
TQ-siRNA cell line was supertransfected with ei-
ther vector alone (V) or DTCF-1. The data shown
are tumor growth kinetics with five mice per
group. The levels of laforin and the DTCF-1 pro-
tein were determined by Western blot, and
a control cell line expressing both DTCF-1 and la-
forin was used as control. Data shown are repre-
sentatives of two experiments.
H: EPM2a expression and increased Wnt signal-
ing in human T cell leukemia and lymphoma
cell lines. Ha: EPM2a expression in human T lym-
phoma cell lines and the response to 5-Aza-dC
treatment. RT-PCR was performed using primers that amplified the entire coding sequence of EPM2a, and b-actin was used as control. Hb: Increased nuclear
accumulation of b-catenin in human T cell lymphoma cell lines. The nuclear extracts were isolated and blotted with anti-b-catenin and anti-E-cadherin. Nu-
clear protein Sp1 was used as loading control, and the absence of membrane marker E-cadherin indicates that the nuclear extracts were free of plasma
membrane contamination. Hc: Induction of EPM2a correlated with reduced Wnt signaling. HH, J45.01, and MJ lines were treated with 5-Aza-dC for 36 hr,
and the nuclear extracts were analyzed for b-catenin accumulation.proteins in the Epm2a-transfected cells, but not in the vector-
transfected cells. Thus, GSK-3b and laforin are associated in
the NIH3T3 cells. To determine whether GSK-3b associates
with endogenous laforin protein, we precipitated the GSK-3b
in untransfected NIH3T3 cells and probed the precipitates with
antibody specific for laforin. As shown in the lower panel of
Figure 7E, significant amounts of laforin were coprecipitated
with GSK-3b. Thus, laforin associates with GSK-3b under phys-
iological conditions. The association between GSK-3b and
laforin was independent of the phosphatase activity and was
independent of stimulation by PDGF (Figure S3).
As a third approach, we tested whether recombinant laforin
can directly dephosphorylate GSK-3b at Ser9 in vitro. We puri-
fied wild-type or mutant laforin protein with V5 tag from 293
transfectants by anti-V5 antibody coupled protein G beads.CANCER CELL SEPTEMBER 2006We used the BSA (bovine serum albumin)-coupled synthetic
N-terminal peptide of the GSK-3b with phosphorylated Ser9
as substrate. Ser9-specific dephosphorylation was detected
using antibodies specific for the phosphorylated GSK-3b Ser9.
As shown in Figure 7F, the wild-type but not the C265S mutant
laforin dephosphorylated the p-Ser9 peptide. The same laforin
preparation, however, failed to dephosphorylate Bad, which
was phosphorylated in vitro by a constitutively active recombi-
nant Akt mutant protein (Figure 7G).
Laforin is an important modulator for Wnt signaling
GSK-3b is amajor component in theWnt signaling pathway (Co-
hen and Frame, 2001). To understand how laforin may suppress
tumor growth, we tested whether it may modulate Wnt signaling
by regulating GSK-3b activity. As shown in Figure 8A, in187
A R T I C L Etransgenic mice that had one copy of the Epm2a inactivated,
the thymocytes had a modest increase of phosphorylated
GSK-3b in the cytosol, although no b-catenin was detected
in the nuclei. In the lymphoma samples that had complete in-
activation of the Epm2a gene, a drastic increase of GSK-3b
phosphorylation and b-catenin accumulation in the nuclei
were observed.
We carried out three lines of investigation to substantiate the
notion that Epm2a may regulate Wnt signaling. First, we ana-
lyzed the effect of overexpressing or silencing the Epm2a ex-
pression in NIH3T3 cells. As shown in Figure 8B, Wnt induced
GSK-3b Ser9 phosphorylation and accumulation of b-catenin
in the nuclei of the vector-transfected cells. Both parameters
were significantly inhibited by Epm2a overexpression. The
phosphatase inactive Epm2a C256S abolished the function of
laforin and restored the Wnt effect on GSK-3b Ser9 phosphory-
lation and nuclear accumulation of b-catenin. The functional im-
portance of laforin expression in b-catenin activity was further
confirmed by a TCR reporter assay (Korinek et al., 1997), as
shown in Figure 8C. Likewise, expression of Epm2a in B104-
1-1 cells inhibited GSK-3b Ser9 phosphorylation and nuclear
accumulation of b-catenin, regardless of whether exogenous
Wnt-3A was added (Figure 8D). We also observed a similar ef-
fect on T cell lymphoma BW5147, that transfection of Epm2a,
but not phosphatase inactive Epm2a-C256S, suppressed nu-
clear accumulation of b-catenin (Figure S4). To test the role of
endogenous laforin in Wnt signaling, we used siRNA to specifi-
cally silence the Epm2a gene in the NIH3T3 cell line. This re-
sulted in a substantial increase of GSK-3b Ser9 phosphorylation
and the nuclear b-catenin accumulation in NIH3T3 cells upon
Wnt-3A induction (Figure 8E).
An interesting issue is whether the increased Wnt signaling
was responsible for the tumorigenesis associated with Epm2a
downregulation. We chose the TSC-2-deficient cell line
LExF2-TQ (Inoki et al., 2003) to test this possibility, as it has in-
creased b-catenin accumulation (Mak et al., 2003), but is not yet
tumorigenic in immunodeficient mice (data not shown). More
importantly, silencing Epm2a substantially increased Wnt sig-
naling in this cell line (Figure S5). We first used the siRNA to si-
lence Epm2a and injected the vector (TQ-V) and Epm2a-si-
lenced (TQ-siRNA) cells into an immunodeficient host. As
shown in Figure 8F, while the vector-transfected cells failed to
produce tumors in the recipients, the Epm2a-silenced cells pro-
duced tumors in vivo. We then supertransfected the Epm2a-
silenced cells with a dominant-negative TCF-1 (DTCF-1) to
block the effector function of Wnt signaling. As shown in
Figure 8G,DTCF suppressed tumor growth induced by silencing
Epm2a. These results demonstrate that laforin suppresses
tumor growth by inhibiting Wnt signaling.
As a first step in determining the relevance of our studies in
human T cell lymphoma, we analyzed a panel of human T cell
lymphoma cell lines for constitutive and 5-Aza-dC-inducible ex-
pression of EPM2a (Figure 8Ha) as well as accumulation of b-
catenin in the nuclei (Figure 8Hb). Of the cell lines tested,
CCRE-CEM, Jurkat, and J45.01 had no detectable EPM2a tran-
scripts. Correspondingly, high levels of b-catenin were found in
the nuclear extracts. In contrast, HH, H9, andMJ had detectable
EPM2a transcripts and very low levels of nuclear b-catenin.
Thus, the depression of EPM2a expression correlates strongly
with enhanced Wnt signaling in human T lymphoma cell lines.
To explore whether hypermethylation is responsible for the188silencing of EPM2a in the T lymphoma, we treated these cell
lines with nontoxic doses of 5-Aza-dC and evaluated expression
of EPM2a. As shown in Figure 8Ha, in most of the cell lines
tested, 5-Aza-dC caused a substantial increase in EPM2a ex-
pression. Moreover, induction of EPM2a expression correlates
with reduced b-catenin (Figure 8Hc). Taken together, our data
suggest that epigenetic repression of EPM2a may play a role
in enhanced Wnt signaling in human T cell lymphoma.
Discussion
Laforin is a tumor suppressor in the mouse
We have presented several lines of evidence that support a role
for laforin as a tumor suppressor. First, we have identified by po-
sition cloning that a line of TCR transgenic mice with rapid onset
and high penetrance of lymphoma has the transgene inserted in
the intron 1 of the Epm2a gene. Since the heterozygous mice
had roughly 50% of laforin protein expression, it is likely that
such insertion inactivated the Epm2a locus. The development
of lymphoma was associated with complete silencing of
Epm2a, which in turn was due to hypermethylation of the
Epm2a promoter. Thus, the genetic lesion and epigenetic inac-
tivation of the Epm2a gene during tumorigenesis was consistent
with the new definition of a tumor suppressor gene (Paige,
2003). Second, we have demonstrated that hypermethylation
of the Epm2a gene is not unique to the mouse lymphomamodel
in the TCR transgenic mice. Downregulation of laforin was
observed in a large panel of mouse lymphoma cell lines and cor-
related with hypermethylation of the locus. Third, we have di-
rectly demonstrated that the transgenic complementation of
Epm2a in the T cell lineage prevented the development of T
cell lymphoma in the TG-B mice. Conversely, suppression of
the Epm2a gene by siRNA increased tumorigenicity of an endo-
thelial cell line, promoted self-renewal ability of bone marrow
hematopoietic stem cells, and caused myelodysplasia in vivo.
Taken together, our data demonstrate that Epm2a inactivation
is both necessary and sufficient for the development of tumor
in our mouse model.
It is of interest to note that while siRNA silencing primarily
caused transformation ofmyeloid cells, essentially all lymphoma
in the TG-B mice were derived from T cell lineage. Since the si-
lencing of the other allele required methylation, and since the
TCR transgene was turned on exclusively in the T cell lineage
(even before cell surface TCR was detected), it is tempting to
speculate that transcription of TCR locusmay increase the likeli-
hood of epigenetic silencing of the other Epm2a allele. On the
other hand, siRNA silencing may disrupt Epm2a at the stem
cell stage and may cause abnormal differentiation and transfor-
mation of myeloid cells, although the number of mice observed
in the siRNA experiments was too small to exclude the possibil-
ity of other lineage of tumors.
An important feature of the Epm2a gene as a tumor suppres-
sor is that it acts primarily in the immunocompromised host, as
the Epm2a-associated tumor phenotype was observed in TCR
transgenic mice that had extremely limited TCR repertoire. In
support of this notion, we have been able to induce leukemia
by silencing Epm2a only in bone marrow of TCR transgenic
mice, but not when the bone marrow stem cells are capable of
giving rise to a full repertoire of T cells. This notion would explain
the lack of report on malignancy in mice with targeted mutation
of Epm2a alone (Ganesh et al., 2002) and in the patients withCANCER CELL SEPTEMBER 2006
A R T I C L ELafora’s diseases caused by homozygous mutations of the
EPM2a. It is worth noting that LOH in 6q24, where the EPM2a
resides (Minassian et al., 1998; Serratosa et al., 1995, 1999), is
one of the most frequent chromosomal alterations in AIDS-
related lymphoma (Pastore et al., 1996).
The immune system has long been suspected as a major bar-
rier to tumorigenesis, as articulated by Ehrlich’s hypothesis of
immune surveillance (Dunn et al., 2004; Ehrlich, 1909). Despite
newly emerged evidence for immune editing of cancers pro-
duced in immune competent hosts (Dunn et al., 2004), the issue
remains controversial (Willimsky andBlankenstein, 2005), in part
because of a lack of genetic lesions that can produce cancer
only in an immunocompromised host. Our study demonstrates
that inactivation of Epm2a is such a lesion.
Laforin is the phosphatase for GSK-3b and a critical
modulator of Wnt signaling in tumor development
GSK-3b is a key modulator for several important signal trans-
duction pathways. Although GSK-3b is inactivated by phos-
phorylation at the Ser9 position, it is unclear if the inactivated en-
zyme can be reactivated by dephosphorylation. While our study
was being considered for publication, Lohi et al. showed that
overexpression of EPM2a led to GSK-3b dephosphorylation at
the Ser9 position (Lohi et al., 2005). However, it is unclear
whether laforin is the specific GSK-3b phosphatase under phys-
iological conditions. Here we provide strong evidence that
laforin is a specific phosphatase for GSK-3b. First, laforin is
constitutively associated with GSK-3b in vivo. Second, re-
combinant laforin protein isolated from either eukaryotic or
prokaryotic cells specifically dephosphorylated Ser9 of GSK-
3b, but not on unrelated Akt targets, such as Bad. Third, trans-
fection of laforin reduced PDGF-induced phosphorylation of
Ser9 of GSK-3b, but not that of Y216 of GSK-3b, Y279 of
GSK-3a, or the phosphorylation of PDK, Akt, and other Akt
substrates such as FKHR and AFX. Moreover, inactivation of
Epm2a in either NIH3T3 cells or in TG-B mice substantially in-
creased phosphorylation of GSK-3b. Finally, transfection of la-
forin substantially increased the enzymatic activity of GSK-3b.
Taken together, our data demonstrate that laforin is a critical
regulator of Ser9 phosphorylation and of the enzymatic activity
of GSK-3b in vivo.
An important issue is whether, by regulating GSK-3b, laforin
can modulate Wnt signaling. Since Drosophila appears to lack
the Epm2a gene (Ganesh et al., 2001), it is unlikely that laforin
is universally required for Wnt signaling. We have taken two ap-
proaches to demonstrate that laforin is an important regulator in
Wnt signaling during tumor development. First, we showed that
overexpression of laforin reduced nuclear accumulation of b-
catenin in response to Wnt-3A, especially when PKC was acti-
vated. Conversely, knockdown of laforin both in tumor cell lines
and in lymphomas that spontaneously arose in TCR transgenic
mice resulted in a dose-dependent increase of b-catenin in the
nuclei. Since nuclear accumulation of b-catenin plays a major
role in tumorigenesis, modulation of Wnt signaling is likely to
be responsible for the laforin-mediated suppression of tumor
growth. Indeed, using a dominant-negative form of TCF-1, we
showed that tumor growth associated with Epm2a silencing de-
pends on Wnt signaling, which indicates that inactivation of
EPM2a may be a critical event in cancer development in the
context of immune suppression.CANCER CELL SEPTEMBER 2006Experimental procedures
Antibody against laforin
Anti-laforin polyclonal antibody was produced by Genemed Synthesis, Inc.
(San Francisco, CA). Rabbits were immunized with the synthetic peptide of
16 amino acid residues (YKFLQREPGGELHWEG, residues 85–100 in laforin
protein, accession number AAD26336) coupled with keyhole limpet hemocy-
anin (KLH) in complete Freund’s adjuvant. The antiserum was purified using
peptide-conjugated Affigel column.
Mice
TG-B mice were housed and bred in OSU ULAR facility. BALB/c, B10.BR,
and RAG-deficient mice were purchased from Jackson Lab. All animal
experiments have been approved by OSU Institutional Animal Care and
Use Committee (IACUC) and conformed to the national guidelines and
regulations.
5-Aza-dC treatment
Cells were seeded at a density of 63 106 cells/10 cm plate and cultured with
5-Aza-dC (Sigma, St. Louis, MO) for 48 hr at maximal tolerable doses based
on a 24 hr viability test (1 mM for P815, 2 mM for EL-4, 3 mM for BW5147, 10 mM
for Yac-1 andMeth A, 20 mM for MC38; for human T leukemia and lymphoma
cell lines: 8 mM for CCRT-CEM, 2 mM for H9, 4 mM for HH, 10 mM for Jurkat,
MJ, J45.01, and Hut-78).
Epm2A siRNA constructs and lentiviral vectors
Oligonucleotides encoding siRNA directed against EPM2a at the C-terminal
region of 934 to 954 nucleotides (50-AAGGTGCAGTACTTCATCATG-30) were
subcloned into pSilencer 1.0-U6 siRNA expression vector (Ambion, Austin,
TX) to generate Epm2a-siRNA according to the manufacturer’s protocol.
Cell fractionation and b-catenin analysis
Vector, Epm2a, or siRNA transfectants of NIH3T3, B104-1-1, or LExF2-TQ
cells were treated with or without recombinant mouse Wnt-3A protein
(500 ng/ml, R&D Systems, Minneapolis, MN) in DMEM medium containing
1% serum (high-dose condition; Figures 8D and 8E) or Wnt3A (20 ng/ml) in
conjunction with 0.5 mM PMA (Figure 8B and Figure S5) for 3 hr. The cells
were either directly lysed for the detection of p-GSK-3b level in total lysate
or homogenized and fractioned for the detection of b-catenin level in the
nuclear extract in Western blots.
Methylcellulose bone marrow colony formation assay
in vitro and bone marrow reconstitution in vivo
The in vitro methylcellulose bone marrow colony formation assay was per-
formed according to a previously described protocol (Lavau et al., 1997).
To test the in vivo transformation, the vector- or Epm2a siRNA-transduced
bone marrow cells from BALB/c.P1CTL (Sarma et al., 1999) (a TCR trans-
genic strain without high incidence of lymphoma and syngeneic the RAG-
22/2 recipient), BALB/c, or B10.BRmice were expanded in the medium con-
taining the above cytokine cocktail for 2–7 days. The expanded bonemarrow
cells were i.v. injected into sublethally irradiated RAG-22/2 mice (2 3 106/
mouse).
PCR in situ hybridization
The DNA probe was generated by amplifying the blasticidin-resistant gene
from pLenti-V5-DTOPO vector (Invitrogen). Sections were prepared from for-
malin-fixed, paraffin-embedded tissue samples, and PCR in situ hybridiza-
tion was carried out according to a previously described protocol (Nuovo
et al., 1999). The PCR reaction was carried out with primers as follows:
BLSD-F, AGC TTG TAT ATC CAT TTT CGG ATC TGA; BLSD-R, TAA AGG
TAC CGA GCT CGA ATT GTG CTT. PCR reaction without primers was
used as control.
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures and
five supplemental figures and can be found with this article online at http://
www.cancercell.org/cgi/content/full/10/3/179/DC1/.189
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